| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Eupalinolide B targets multiple signaling pathways involved in cancer cell survival and proliferation. It has been shown to inhibit tumor cell proliferation and induce apoptosis by disrupting key signaling pathways such as STAT3 and NF-κB. By interfering with these pathways, it effectively suppresses the growth and survival of cancer cells.
|
|---|---|
| ln Vitro |
In vitro, Eupalinolide B demonstrates potent cytotoxicity against several tumor cell lines. It is particularly effective against A-549 (lung cancer), BGC-823 (gastric cancer), and HL-60 (leukemia) cells. This broad-spectrum activity highlights its potential as a lead compound for anticancer drug development. Its activity is likely mediated by the induction of apoptosis and cell cycle arrest.
|
| ln Vivo |
In vivo, the efficacy of Eupalinolide B has not been extensively reported. However, its strong in vitro activity and its mechanism of inhibiting key survival pathways like STAT3 and NF-κB suggest that it could be effective in vivo as well. Further studies in animal models are needed to confirm its therapeutic potential and pharmacokinetic properties.
|
| Enzyme Assay |
The in vitro cytotoxicity assay for Eupalinolide B is the primary method for evaluating its activity. Tumor cell lines, such as A-549, BGC-823, and HL-60, are cultured in 96-well plates and treated with varying concentrations of the compound. After 48-72 hours of incubation, cell viability is assessed using a standard colorimetric assay like MTT or SRB, from which the IC50 value is determined.
|
| Cell Assay |
In vitro cell culture studies for Eupalinolide B involve detailed mechanistic investigations. Treated cancer cells are analyzed for apoptosis using Annexin V/PI staining and flow cytometry. Cell cycle distribution is assessed by propidium iodide staining. The expression of signaling pathway proteins like STAT3 and NF-κB, as well as apoptotic markers like caspases and PARP, is analyzed by Western blotting to confirm the mechanism of action.
|
| Animal Protocol |
In vivo animal experiments for Eupalinolide B would typically involve xenograft models. Immunodeficient mice are implanted with human tumor cells (e.g., A-549 lung cancer cells). Once tumors are established, Eupalinolide B is administered, typically via intraperitoneal injection. Tumor growth is monitored over time, and at the end of the study, tumors are excised and analyzed for histopathology and molecular markers.
|
| ADME/Pharmacokinetics |
Eupalinolide B has a molecular weight of 462.49 g/mol and is a solid compound. It is slightly soluble in water (3.6 g/L at 25°C) and is more soluble in organic solvents like DMSO. It is typically stored as a powder at -20°C. For in vitro studies, stock solutions are prepared in DMSO and diluted in cell culture media.
|
| Toxicity/Toxicokinetics |
Toxicological data for Eupalinolide B are limited to in vitro cytotoxicity assessments. Its potent effects on cancer cells suggest it could be toxic to normal cells at high concentrations. As a research compound, it is not intended for human use, and comprehensive in vivo toxicity studies are not available. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
Reports indicate that Eupalinolide A has been discovered in Eupatorium lindleyanum, and relevant data is available for reference.
Eupalinolide B is a research compound with no clinical approval. It is a valuable natural product for studying the anticancer mechanisms of sesquiterpene lactones. Its ability to inhibit STAT3 and NF-κB, two major oncogenic pathways, makes it a promising lead compound for drug discovery, particularly for cancers that are dependent on these pathways for survival and growth. |
| Molecular Formula |
C₂₄H₃₀O₉
|
|---|---|
| Molecular Weight |
462.49
|
| Exact Mass |
462.188
|
| CAS # |
877822-41-8
|
| PubChem CID |
71463992
|
| Appearance |
White to off-white solid powder
|
| Density |
1.24±0.1 g/cm3 (20 ºC 760 Torr)
|
| Boiling Point |
618.6±55.0 °C at 760 mmHg
|
| Flash Point |
205.4±25.0 °C
|
| Vapour Pressure |
0.0±4.1 mmHg at 25°C
|
| Index of Refraction |
1.541
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
33
|
| Complexity |
909
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C/C/1=C\[C@@H]2[C@@H]([C@@H](C/C(=C/C[C@@H]1OC(=O)C)/COC(=O)C)OC(=O)/C(=C/CO)/C)C(=C)C(=O)O2
|
| InChi Key |
HPWMABTYJYZFLK-FHEQDPKSSA-N
|
| InChi Code |
InChI=1S/C24H30O9/c1-13(8-9-25)23(28)32-21-11-18(12-30-16(4)26)6-7-19(31-17(5)27)14(2)10-20-22(21)15(3)24(29)33-20/h6,8,10,19-22,25H,3,7,9,11-12H2,1-2,4-5H3/b13-8+,14-10+,18-6-/t19-,20+,21+,22-/m0/s1
|
| Chemical Name |
[(3aR,4R,6Z,9S,10E,11aR)-9-acetyloxy-6-(acetyloxymethyl)-10-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] (E)-4-hydroxy-2-methylbut-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~216.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1622 mL | 10.8110 mL | 21.6221 mL | |
| 5 mM | 0.4324 mL | 2.1622 mL | 4.3244 mL | |
| 10 mM | 0.2162 mL | 1.0811 mL | 2.1622 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
